Acupuncture Reduces Fatigue, Anxiety, Depression in Some Breast Cancer Patients
the Cancer Therapy Advisor take:
Electroacupuncture (EA) is a form of acupuncture where a small electric current passes between two acupuncture needles.
According to data from a randomized, placebo-controlled trial recently published in Cancer and led by researchers at the Perelman School of Medicine at the University of Pennsylvania, the use of EA in patients with early-stage breast cancer who have experienced joint paint related to aromatase inhibitors (AIs) produced a significant improvement in fatigue, anxiety, and depression.
The benefits of EA were seen as soon as 8 weeks after initial treatment. This is the first research to demonstrate efficacy of EA for the common symptoms of depression, anxiety, and fatigue. This study is a follow up to research from November 2013 that indicated EA could decrease joint paint in approximately 50% of patients with breast cancer who were taking AIs, the most commonly prescribed medications to prevent the recurrence of breast cancer in post-menopausal women with early-stage, hormone receptor–positive disease.
Although AIs are very effective, the side effects can affect quality of life and the joint pain caused by AIs is believed to lead to anxiety, sleep disturbance, fatigue, and depression. Researchers theorize that these side effects can lead to nonadherence, and previous studies have shown that nonadherence to AIs can lead to a higher change of death.
This study gives oncologists a better understanding of how symptoms like fatigue and psychological distress relate to pain in patients with AI-related joint pain and indicates that EA may be an effective treatment for a number of patients who experience these symptoms.
Use of EA produces significant improvements in fatigue, anxiety and depression.
Use of electroacupuncture (EA) -- a form of acupuncture where a small electric current is passed between pairs of acupuncture needles -- produces significant improvements in fatigue, anxiety and depression in as little as eight weeks for early stage breast cancer patients experiencing joint pain related to the use of aromatase inhibitors (AIs) to treat breast cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC